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Background: Although rare diseases have become a major public health issue, there is a paucity of population-based
data on rare diseases. The aim of this epidemiological study was to provide descriptive figures referring to a sizable
group of unrelated rare diseases.
Methods: Data from the rare diseases registry established in the Veneto Region of north-east Italy (population
4,900,000), referring to the years from 2002 to 2012, were analyzed. The registry is based on a web-based system
accessed by different users. Cases are enrolled by two different sources: clinicians working at Centers of expertise
officially designated to diagnose and care patients with rare diseases and health professionals working in the local
health districts. Deaths of patients are monitored by Death Registry.
Results: So far, 19,547 patients with rare diseases have been registered, and 23% of them are pediatric cases. The
overall raw prevalence of the rare diseases monitored in the population under study is 33.09 per 10,000 inhabitants
(95% CI 32.56-33.62), whilst the overall incidence is 3.85 per 10,000 inhabitants (95% CI 3.67-4.03). The most
commonly-recorded diagnoses belong to the following nosological groups: congenital malformations (Prevalence:
5.45/10,000), hematological diseases (4.83/10,000), ocular disorders (4.47/10,000), diseases of the nervous system
(3.51/10,000), and metabolic disorders (2,95/10,000). Most of the deaths in the study population occur among pediatric
patients with congenital malformations, and among adult cases with neurological diseases. Rare diseases of the central
nervous system carry the highest fatality rate (71.36/1,000). Rare diseases explain 4.2% of general population Years of
Life Lost (YLLs), comparing to 1.2% attributable to infectious diseases and 2.6% to diabetes mellitus.
Conclusions: Our estimates of the burden of rare diseases at population level confirm that these conditions are a
relevant public health issue. Our snapshot of their epidemiology is important for public health planning purposes,
going to show that population-based registries are useful tools for generating health indicators relating to a
considerable number of rare diseases, rather than to specific conditions.
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Rare diseases have become a topical issue in the medical
and societal debate. After being ignored for some time,
this topic has been attracting increasing attention and
come to be recognized as a priority to consider both in re-
search programs and in health policy implementation [1].
Rare diseases often reportedly have a considerable im-
pact on the health of a community in terms of the related
impairments, long-term disabilities and shorter life-
expectancy, as well as high human and social costs [2,3].
Although more attention has been addressed to this issue
of late, only a few population-level snapshots of the im-
pact of rare diseases are currently available. It has been es-
timated, for example, that rare diseases are responsible for
about one in three cases of severe impairment in children
[4]. There is a general shortage of epidemiological data on
many rare diseases, making it impossible to calculate the
true burden of these conditions as a whole in terms of
years of life lost due to premature death, those lost due to
disability, and so on [5]. The paucity and fragmentation of
available data also make it difficult to compare the burden
attributable to rare diseases with the one due to other
more common diseases, injuries or risk factors, and such
comparisons are fundamental to health care decision-
making and planning at population level [6,7].
Despite the urgent need for reliable data, the epi-
demiological figures on rare diseases are objectively diffi-
cult to collect for a number of reasons.
The first issue concerns how to clearly establish which
diseases should be defined as rare. Between 5,000 and
8,000 rare diseases are believed to exist, but these figures
are continuously being adjusted as new forms come to
light [8]; and several different definitions of rare disease
are in use around the world [9-13].
The second problem is how to trace patients with rare
diseases in public health information systems. The Inter-
national Classification of Diseases (ICD) [14] has some
limitations when it comes to coding and classifying most
rare diseases, and consequently in identifying the pa-
tients involved [15]; just to give an example, ICD-10
provides a specific code for less than 250 rare diseases
[16]. In the context of the ongoing ICD revision process,
a specific Topic Advisory Group has been established
for rare diseases, with a view to improving the coding
and classification of these conditions [17]. Orphanet co-
ordinates this activity, and has also developed an inven-
tory of rare diseases. A unique identifier, called ORPHA
number, is assigned to each rare disease [18]. In France,
one of the key actions of the second French Plan for
rare diseases was put in place: ORPHA numbers have
entered in use in hospital information systems, allowing
a better traceability of rare diseases patients’ into the
healthcare system. Of course, the effect of this effort will
be observable only in some years from now.For all the above reasons, the availability of reliable
epidemiological data on rare diseases is increasingly per-
ceived as a strong and urgent need. At European level,
the Council Recommendation on an action in the field
of rare diseases, issued in 2009, has recognized the
importance of supporting specific disease information
networks, registries and databases [19]. The attention of
all the interested parties involved (researchers, patients
with rare diseases, governmental bodies, etc.) is focusing
on choosing the best methods for systematically collect-
ing data on rare disorders. Some countries have taken
steps to develop platforms to facilitate the collection of
disease-specific data. In the USA, a movement involving
both researchers and patients supported the develop-
ment of a global rare diseases registry for collecting
a considerable amount of information on potentially
thousands of diseases and linking these data with bio-
repositories [20,21].
On the European front, Orphanet periodically provides
a snapshot of the data being collected on rare diseases by
588 databases and registries [22]; the vast majority of the
sources listed by Orphanet are maintained by public insti-
tutions (academia), while very few involve governmental
bodies. They differ in terms of data sources, structure,
tools used for data collection and coverage.
An important distinction has to be made between pa-
tient databases and registries. Patient databases are not
designed to provide a full coverage of the population,
so they cannot be used to estimate the prevalence/inci-
dence of the diseases monitored. Such figures can only
be obtained from the data in registries, a prerequisite of
which is to define an accurately-monitored catchment
area in which all registered cases arise (usually a region
or a country) [23]. Many population registries have
been set up to gather information on the epidemiology
of certain rare diseases. They usually focus on single
conditions or groups of diseases, such as congenital
malformations [24]. Though they are important, such
data registries are challenging to establish and main-
tain, and it is difficult to judge their ability to describe
the epidemiology and global burden of rare diseases at
population level [25].
In 2011, the European Commission launched the
EPIRARE project with a view to establishing the require-
ments for rare disease registries and databases, to ex-
ploring the feasibility of defining a dataset shared by
different rare disease registries, and to developing a
common platform for the exchange of data. More re-
cently, EUCERD issued a set of recommendations con-
cerning the registration of rare diseases and the related
data collection, according to which rare disease registries
should be organized around population health needs
and/or single rare diseases, or groups of rare diseases,
rather than around their treatments [26].
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rare diseases has been recognized particularly as con-
cerns two aspects: to assess the health status and health
outcomes of patients, and to monitor the efficacy of
health policies and initiatives addressed to rare diseases.
The use of data from registries dedicated to one or more
rare diseases has been identified as strategically import-
ant to ensure the availability of many such health indica-
tors [27]. In practice, this can only be done for some
rare diseases, for which good-quality data collection
schemes are already in place. A more comprehensive ap-
proach is required, however, to produce indicators that
refer - if not to the whole “universe” of rare diseases - at
least to a significant proportion of them. To achieve this
goal, it is mandatory to adopt a population-based ap-
proach, even though this is usually considered very diffi-
cult and expensive.
The Italian rare diseases scenario has something to con-
tribute to the debate on this complex issue. Here we de-
scribe the experience gained in this field by the Veneto
Region’s rare diseases registry (VR-RDR) in the north-east
of Italy. A multi-source web-based information system has
been developed that combines aspects of a population-
based registry (an essential source of epidemiological data
for supporting health planning) with aspects of a more
clinically-oriented registry (collecting data that are useful
in the clinical decision-making process). The registry was
implemented in the Veneto Region in 2002 and has since
then been adopted successfully in other Italian regions
(Trentino-Alto Adige, Emilia-Romagna, Liguria and, more
recently, Campania, Apulia, Umbria and Sardinia).
The main aim of the present study is to describe the
epidemiological figures relating to a group of rare dis-
eases in the Veneto Region emerging from this first
Italian population-based registry dedicated to rare diseases
and covering the years from 2002 to 2012, particularly as
concerns prevalence, incidence, mortality, fatality rate, and
years of life lost.
Methods
Italian legislation on rare diseases
The Italian health-care system is a universal, regionally-
based public system. A law defining Italian policy on
rare diseases was issued in 2001 [28]. The key elements
of this legislation are: the establishment of a list of rare
diseases, the identification of regional/inter-regional
Centers of expertise for rare diseases responsible for pa-
tient diagnosis and follow-up, and the creation of area-
based rare disease registries.
The list of rare diseases
The list of rare diseases attached to the Italian Law estab-
lishes which patients are entitled to benefits and facilitated
access to care. The list contains 331 single diseases orgroups of disorders divided into 14 nosological categories,
based on the ICD9-CM [see Additional file 1]. For the
groups, only a few examples of the relevant diseases are
mentioned in the law. As a preliminary step, the medical
team developing the registry properly identified all the
diseases to consider (for which patients are eligible for
benefits) in the light of the medical literature and existing
databases. This also involved dealing with synonyms
and eponyms. In addition, corresponding codes as used
in international classifications (i.e. ICD9-CM, ICD-10,
MIM and ORPHA-code) were assigned to each disease.
The resulting list is continuously updated as new forms
are described and new classifications are adopted. Consid-
ering the diseases included in all the groups and the
disease sub-types, nearly 3,000 conditions have been iden-
tified, although some diseases, or groups of diseases, that
qualify as rare are not currently covered by our monitor-
ing system. Excluding rare cancers (which are recorded in
the regional cancer registry), the conditions monitored by
the rare disease registry represent 58% of all the rare dis-
eases included in the Orphanet list.
The care network
In 2002 the Veneto Regional Authority officially identi-
fied the Centers dedicated to the diagnosis and treat-
ment of patients with rare diseases. In 2004 a formal
collaboration agreement between four neighboring re-
gions and provinces in the north-east of Italy (including
the Veneto) led to the identification of a shared inter-
regional network of Centers of expertise for specific
groups of rare diseases (e.g. rare hematological condi-
tions, rare neurological disorders, etc.); each Center has
at least one clinical ward. These Centers were identified
officially on the grounds of indicators and criteria estab-
lished by the Regional Health Authorities signing the
collaboration agreement and they are monitored con-
tinuously. The Centers of expertise are closely linked to
the territorial network of public health services provid-
ing primary and specialized care, as well as non-medical
services for patients with rare diseases. All health care
providers involved in caring for patients with rare dis-
eases use a common information system (IS) to share
clinical data and support the delivery of benefits and ser-
vices to patients. At the same time, the system provides
the foundations for an area-based registry recording data
on patients with rare diseases.
The information system (IS)
Contents
The information system connects the Centers of expertise,
located at 12 different hospitals, via a protected network
(Regional Health Network Intranet) to all the local
public health authorities and all the local and hospital
pharmaceutical services in the Veneto Region. This
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based web browser application that populates a single, cen-
tral Oracle database with a three-level architecture capable
of collecting and managing large amounts of data. L-DAP
has been implemented to manage access by encrypted users
with different personal profiles.
The system collects a set of patients’ socio-demographic
details, such as name, date and place of birth, gender, fis-
cal code, place of residence and, where applicable, place
and time of death. The core element in the information
system is the diagnosis of a rare disease included in a list
shared by all users and regularly updated, as mentioned
earlier. Specific forms have been developed over the years
to manage the drug and dietary prescriptions, medical de-
vices and prosthetics provision, and to collect each pa-
tient’s medical history. Several technical solutions have
been developed to ensure a high-quality data input (with
the completion of mandatory fields, data validation by
checks on data format and plausibility, dropdown lists,
provisional and final data-saving options, etc.). Reported
errors or modifications are managed centrally. Double en-
tries are prevented by the system, except when the same
patient is diagnosed with two different rare diseases.
Users
To access the system, every user is assigned a personal user
name and password. The system assures a high standard of
security. It is accessible to users via a standard browser
using encrypted log-in sessions, in compliance with the
Italian legislation on personal data protection [29].
The system is accessible to: (1) clinicians working at
the Centers of expertise who input patients’ data (demo-
graphic details, diagnosis, prescribed treatments, clinical
data, etc.); (2) health-care providers working in the pri-
mary care setting (local public health districts), who can
view information they are entitled to see and input pa-
tient data that are monitored by the Centers of expertise
located outside the Veneto and collaborating regions; (3)
pharmacists working in the local health districts and in
hospitals who view prescriptions directly and issue medi-
cations to patients according to the treatment plan for-
mulated by clinicians at the Centers of expertise; (4)
other clinicians working in hospitals and directly in-
volved in the patients’ care.
For the moment, general practitioners do not have ac-
cess to the system for security reasons (because most
GPs do not have direct access to the protected regional
intranet system). There are plans to find technical solu-
tions in the near future to enable them to connect to the
platform and share information with the clinicians at the
Centers of expertise in charge of their patients.
All users received training before the system was im-
plemented and updates when new modules were added
to the core system. A help line is managed by trainedregistry personnel and can be contacted to deal with
any questions.
Currently, more than 3,484 health-care professionals
access the system (1,224 in the Veneto Region, and
2,260 in the other regions where the system is used);
those in the Veneto Region include 508 clinicians work-
ing at the Centers of expertise, 450 users at the local
public health districts, and 233 pharmacists.
The patient’s pathway
In practical terms, a patient is referred to a given Center
of the network for a complete assessment (which is free
of charge when a rare disease is suspected). If a rare dis-
ease is diagnosed, this implicitly involves the clinician at
the Center issuing a certificate and, at the same time,
the local public health authority of the patient’s place of
residence issuing an exemption document. Patients can
thus receive the benefits to which they are legally enti-
tled, including specific drugs or medical devices indi-
cated in the treatment plan drawn up at the Center of
expertise. In this way, the case is registered in the infor-
mation system, thus providing the foundations for an
area-based registry of patients with rare diseases.
Setting
The population monitored includes all residents in the
Veneto Region, i.e. a population of 4,853,657 as at 2012
(source: Italian National Institute of Statistics).
Eligible cases are all patients diagnosed with one of the
rare diseases on the list in the Italian law (see Additional
file 1) and registered in the information system from May
1, 2002 to December 31, 2012.
Cases are identified using two possible alternative
sources of input data, i.e. the clinicians working at the
Centers of expertise in the Veneto and the other re-
gions sharing the same IS, or health professionals work-
ing at the local public health districts who input data
on patients diagnosed and followed up by Centers of
expertise outside the inter-regional area being moni-
tored. This ensures a good coverage of the Veneto’s
resident population.
Other data sources and indicators
To ensure that almost all patients diagnosed with one of
the monitored diseases are enrolled in the registry,
cross-referencing with other regional data sources is
done at regular intervals. These other sources include
the registry of hospital discharge records, the birth regis-
try, the records of outpatient rehabilitation services, and
the death registry.
The following indicators were calculated with a 95%
confidence interval from registry data, by age group
(0–12 months; 1–14 years, 15–17 years; 18–64 years;
over 65 years old) and by nosological group: prevalence,
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the results for the interval between 1 May 2002 and 31
December 2012, estimating the point prevalence as at 31
December 2012.
To calculate the years of life lost (YLLs) we consid-
ered life expectancies by age and gender based on life
tables by age and gender referring to the Veneto popu-
lation (source: Italian National Institute of Statistics,
year 2010).
Our statistical analysis was performed using the SAS
package, rel. 9.1 (SAS Institute Inc., Cary, NC, USA).
Results
During the period from May 2002 through December
2012, there were 19,547 individuals diagnosed with one of
the rare diseases listed in the Italian Law (see Additional
file 1) among the population monitored. Another 4,405
patients were diagnosed at Centers of expertise in the
Veneto Region, but lived outside the study area, yielding a
total of 23,952 cases recorded in the registry, and 1,424
different rare diseases diagnosed; 56 individuals had more
than one rare disease.
Of the 19,547 patients who lived in the study area,
52% were female and 48% male. The registered patients
were a mean 38 years old. Of the patients alive as at 31
December 2012, 23% were under 18 years of age. The
overall raw prevalence of rare diseases in the study
population was 33.09 per 10,000 inhabitants (95% CI
32.56-33.62) (Table 1).
The prevalence among infants under 1 year old was
25.73 per 10,000 newborns (95% CI 21.23-30.24), with
an overall prevalence in pediatric patients (0 to 17 years
old) of 44.05 per 10,000 (95% CI 42.61-45.49). The
prevalence of rare diseases was 31.34 and 17.68 per
10,000 inhabitants in the 18–64 and ≥65-year-old age
groups, respectively.
The overall raw annual incidence of rare diseases
was 3.85 per 10,000 inhabitants (95% CI 3.67-4.03),
corresponding to nearly one new case a year for everyTable 1 Prevalence, incidence, mortality and fatality rates by
Prevalence per 10,000 Crude incidence per
Age Rate C.I. 95% Rate C.I. 95
0-17 years 44.05 42.61-45.49 3.96 3.52-4
0-12 months 25.73 21.23-30.24 25.73 21.23-
1-17 years 45.22 43.71-46.72 4.26 3.80-4
1-14 years 46.25 44.58-47.93 4.41 3.89-4
15-17 years 40.26 36.84-43.68 3.57 2.55-4
18-64 years 31.34 30.72-31.96 3.70 3.48-3
over 65 years 17.68 16.83-18.53 2.90 2.56-3
TOTAL 33.09 32.56-33.62 3.85 3.67-
Veneto Region’s rare diseases registry. * rate per 1,000 live births.10 prevalent cases (Table 1). The incidence in 1- to
17-year-olds was 4.26/10,000 (95% CI 3.80-4.73). The
annual incidence rates for the 18- to 64- and the ≥65-
year-olds were 3.70 and 2.90 per 10,000 inhabitants,
respectively.
The annual raw mortality rate for patients with rare
diseases was 13.04 per 100,000 inhabitants (95% CI
12.02-14.06). The overall infant mortality rate was 0.56
per 1,000 live births (vs 2.8 in the general population),
and the neonatal mortality rate was 0.16 per 1,000 live
births (vs 2.2 in the general population). As for the post-
neonatal mortality rate, this was 0.4 per 1,000 live births
in the monitored population, two thirds of the rate ob-
served in the general population (0.6 per 1,000 live
births). The overall mortality rate was 7.29 per 100,000
(95% CI 6.69-7.90) among the 1- to 17-year-olds, 9.03
for the 18- to 64-year-olds, and 28.51 for the ≥65-
year-olds.
When age at death was compared between rare disease
patients and the general population, the former were
likely to die mainly in older age classes (but earlier than
members of the general population) and in the first year
of life (Figure 1).
As concerns life expectancy, deaths in the rare disease
population accounted for 14,558 years of life lost, corre-
sponding to 4.2% of the total years of life lost by the
general population - nearly four times as many as the
YLLs due to infectious diseases (1.2%), and nearly twice
as many as the YLLs due to diabetes (2.6%).
The overall annual raw fatality rate was 5.99 per 1,000
(95% CI 4.58-7.40) (Table 1). As expected, the highest fa-
tality rates were seen for infants aged <1 year (19.23 per
1,000) and cases ≥65 years old (26.79 per 1,000).
Table 2 shows the incidence, prevalence, mortality and
fatality rates by nosological group according to the
ICD9-CM.
The nosological groups with the highest prevalence were
congenital malformations (5.45/10,000), hematological
diseases (4.83/10,000), and eye disorders (4.47/10,000),age group
10,000 Mortality per 100,000 Fatality per 1,000
% Rate C.I. 95% Rate C.I. 95%
.39 10.21 8.01-12.41 3.59 1.37-5.81
30.24 0.56* 0.35*-0.77* 19.23 4.74-33.72
.73 7.29 6.69-7.90 2.98 0.92-5.04
.92 8.00 7.30-8.69 3.10 0.81-5.39
.59 3.93 2.86-5.00 2.36 0.00-6.99
.91 9.03 7.97-10.09 3.70 2.33-5.07
.25 28.51 25.10-31.91 26.79 17.49-36.10















Figure 1 Age at death in patients with rare diseases and in the
general population. Veneto Region’s rare diseases registry, Italian
National Institute of Statistics (ISTAT).
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10,000), and metabolic disorders (2.95/10,000). The dis-
tribution by nosological group and age clarifies their
different contribution to the burden of pediatric and
adult disease (Figure 2).
Congenital malformations were involved in 43% of all
rare disease patients under 17 years old as opposed to
9.9% of patients ≥18 years old. Most of the children di-
agnosed with congenital malformations had complexTable 2 Prevalence, incidence, mortality and fatality rates by
GROUPS OF DISEASES (ICD9-CM) Prev
per
Infectious and parasitic diseases 0.05
Neoplasms 1.37
Endocrine disorders 1.05
Disorders of amino-acid transport and metabolism 0.61
Disorders of carbohydrate transport and metabolism 0.22
Disorders of lipoid metabolism 0.22
Disorders of mineral metabolism 1.65
Disorders of plasma protein metabolism 0.06
Metabolic disorders (others) 0.19
Immunity disorders 1.23
Diseases of the blood and blood-forming organs 4.83
Central nervous system disorders 1.79
Peripheral nervous system disorders 1.72
Disorders of the eye and adnexa 4.47
Diseases of the circulatory system 1.12
Diseases of the digestive system 0.63
Diseases of the genitourinary system 0.19
Diseases of the skin and subcutaneous tissue 1.20
Diseases of the musculoskeletal system and connective tissue 2.76
Congenital anomalies 5.45
Certain conditions originating in the perinatal period 0.03
Veneto Region’s rare diseases registry.syndromes (36.5% of cases) or chromosomal anomalies
(28.3%); a non-negligible proportion of them had con-
genital anomalies involving the digestive system (11.2%).
One in two patients ≥18 years old had complex syn-
dromes (23.2%) or chromosomal anomalies (29.7%), as
in the pediatric population. A sizable proportion of pa-
tients had malformations involving the musculoskeletal
system (17.8%) and skin (10.9%), i.e. epidermolysis bul-
losa and ichthyoses.
Hematological diseases (15.5%) formed the second lar-
gest group of 0- to 17-year-olds, due to a high preva-
lence of thalassemia and sickle cell disease in the study
area, the former resulting from an endemic diffusion,
the latter relating to the high immigration rate in the re-
gion considered [30,31]. Hereditary metabolic diseases
were diagnosed in 8.7% of all pediatric patients. The
most common sub-groups of these disorders concerned
the metabolism and transportation of amino acids and
carbohydrates. For 5.8% of the <17-year-old patients di-
agnosed with rare diseases, the problem concerned the
nervous system, and most of these patients had muscu-
lar dystrophies.
The distribution of patients by nosological group changed
in the adult population. The rare diseases most often en-




























































































































































































Figure 2 Percentage distribution of prevalence and mortality rates by nosological group. Veneto Region’s rare diseases registry; cases
0–17 years vs ≥ 18 years old.
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tions (15.7%) - particularly hereditary coagulation de-
fects and hereditary anemias. The percentage of patients
with nervous system diseases was nearly twice as high in
adults as in the pediatric age group (13% vs 5.8%). Whilst
peripheral and central nervous system (CNS) diseases
were equally represented among pediatric patients, adults
had a higher proportion of CNS diseases, amyotrophic lat-
eral sclerosis (ALS) being the most frequent diagnosis.
Interestingly, congenital malformations (9.9%) and meta-
bolic disorders (9.8%) accounted for a non-negligible pro-
portion of rare disease cases in the adult population.
When the mortality data for the pediatric study popu-
lation were considered, congenital malformations were
responsible for 36.5% of deaths, followed by metabolic
disorders (20.6%) and nervous system diseases (20.6%).
While these three groups of rare conditions accountedfor nearly half of all the prevalent cases among pediatric
patients (57.5%), they were responsible for two thirds of
the deaths in children and adolescents (77.7%).
Though neurological diseases only involved 13% of all
the adult patients, they were the cause of more than half of
the deaths in the adult and elderly population monitored
by the registry, due mainly to ALS. The very poor progno-
sis associated with this diagnosis explains the very high fa-
tality rate recorded for rare CNS diseases in the population
monitored (71.36/1,000) (Table 2). Some other nosological
groups coincided with high fatality rates too, despite a rela-
tively small number of patients being involved; this was the
case of rare skin diseases (19.11/1,000), perinatal conditions
(19.36/1,000), and rare diseases of the circulatory system
(14.06/1,000). Protein metabolism disorders also carried a
high fatality rate, due mainly to the large percentage of fatal
cases among patients with mixed cryoglobulinemia.
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the lowest fatality rates, reflected in the long-term sur-
vival of patients with these chronic conditions.
Moreover, the Registry allows to provide, among noso-
logical groups, the real number of cases per specific dis-
ease, classified according to ICD code, or ORPHA
number or MIM number. As an example, at 31th Decem-
ber 2012, 79 cases of Duchenne dystrophy, 316 cases of
Hemophilia A, 52 of Hemophilia B and 18 of Hemophilia
C were recorded in the Registry.
Discussion
As far as we know, the epidemiological figures reported
here, derived from a population-based registry monitor-
ing a broad group of unrelated rare conditions, provide
the first indication of the magnitude of the public health
problem associated with rare diseases.
The snapshot provided by this study of the impact of
rare diseases on different age groups of the population
shows the differences in the distribution of the various
nosological entities. One in three patients with rare dis-
eases is a pediatric case. In this age group, the most
commonly seen rare diseases (congenital malformations,
hematological diseases and inherited metabolic diseases)
are characterized by a potentially high severity, as dem-
onstrated by the corresponding fatality and mortality
data. The epidemiological figures for the pediatric popu-
lation confirm the importance of the neonatal period for
early diagnosis and treatment, and for improving out-
comes. Data from population-based registries that enable
the numbers of cases of rare disease to be estimated are
important for the purpose of optimizing the organization
and functioning of the expanded neonatal screening pro-
grams as they become available [32,33]. In this evolving
scenario, the value of information systems capable of
supporting patients’ long-term follow-up has already
been recognized, with a view to monitoring outcomes
and assessing the utility of any programs implemented
[34,35].
In our adult sample population, the rare diseases most
often identified were eye disorders that are generally a
cause of disability rather than mortality. Another consid-
erable proportion of the adult patients had rare neuro-
logical diseases: this group accounted for half of all
deaths and carried a correspondingly high fatality rate,
attributable mainly to ALS. These data should orient the
allocation of resources, supporting specific measures to
address the health care needs of patients with these con-
ditions [36].
Our registry data go to show that quite a lot of pa-
tients survive into adulthood, especially among those in
certain nosological groups, such as congenital anomalies
[37,38]. Nearly 10% of the adult patients in our sample
population had complex congenital malformations, andone in two patients registered with a diagnosis of inborn
errors of metabolism was over 18 years old, which indi-
cates a longer survival than in previous studies [39,40].
We consider these findings of great interest because they
have important implications in terms of the need to de-
velop new models of health care provision, like those
already adopted for some rare conditions [41-45], which
will have to be extended to more and more patients with
rare diseases surviving into adulthood [46].
On a European level, the production of public health
indicators in the area of rare diseases, like those already
generated for perinatal conditions and congenital anom-
alies [47,48], has been strongly advocated. Such public
health indicators, derivable only from population-based
registries, are particularly important for the purpose of
implementing and monitoring policies specifically ad-
dressing rare diseases. The availability of epidemiological
data is crucial, for example, when it comes to deciding
how many Centers of expertise are needed for each type
of rare disease (depending on the patients’ distribution),
or to setting up and assigning functionalities to other
healthcare providing networks with the particular prob-
lems posed by rare diseases in mind (e.g. rehabilitation
and palliative care services).
Health indicators of extensive use, such as YLLs, are
utilized to assess the burden of diseases on the general
population to guide health policies and public funding.
The present study highlights that rare diseases’ impact
on population health is 2–4 times higher than other
causes on which health policies and public funding focus
at most.
When trying to obtain public health indicators on
rare diseases, the advantages of using health statistics
referring to large populations are limited by patient
traceability problems because rare diseases are under-
represented in current coding and classifications systems
[49]. On the other hand, it would be too costly to estab-
lish and maintain multiple rare disease registries cover-
ing large populations. The dilemma concerning which
sources to use to obtain reliable health indicators on
rare diseases might be solved by a combined approach.
Current statistics could be used (bearing the above-
mentioned limitations in mind) to obtain estimates for
basic indicators until the new ICD (in which rare dis-
eases are more appropriately represented) has come into
use. At the same time, specific systems for monitoring
rare diseases already implemented in certain geograph-
ical areas and different countries could serve as data
sources (so long as they are sufficiently broad-based) for
the purpose of establishing specific indicators and enab-
ling projections for the population of a country or the
whole of Europe.
According to the prevalence data emerging from our
study on the rare diseases considered here (3.3/1,000
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other data sources (Orphanet) for unmonitored entities
(3.3/1,000 inhabitants), we can estimate an overall preva-
lence of rare diseases of 6.6/1,000 inhabitants, which
rises to 12.8-19.5/1,000, according to the other more or
less conservative estimates of the prevalence of rare can-
cers considered [50,51].
Judging from these figures, we can assume that be-
tween 6,500,000 and 9,880,000 people living in the EU28
countries have a rare disease, which corresponds to
1.3%-2% of the whole population. This figure differs
somewhat from the usually-reported estimates of 6-8%
of the whole European population suffering from rare
diseases [52], a difference that can probably be explained
by the fact that the latter higher figures are not derived,
to the best of our knowledge, from epidemiological stud-
ies conducted at population level. On the other hand,
given the previously-mentioned limits of our study, the
figures reported here should be considered as minimum
values. In the light of the above figures, some of the
concerns voiced about the financial sustainability of
health policies specifically addressing patients with rare
diseases in times of economic austerity need to be care-
fully reconsidered. Moreover, indicators of the burden
of rare diseases are probably underestimated to some
degree, in which case the already far from negligible
impact of these conditions at population level is bound
to be even greater.
Limitations
Although this descriptive population-based study pro-
vides insight into the epidemiology of a sizable group of
rare diseases being monitored by a unique web-based
population registry, it has some limitations that need
to be mentioned. First, the data presented here could
underestimate the phenomenon because the registry
may not have enrolled all the individuals living in the
area monitored. This could be the case of patients with
a rare disease that has yet to be diagnosed (diagnostic
delays are known to be common for these rare condi-
tions) [53,54], or patients with severe forms of disease
who were not registered due to early mortality. Elderly
cases may have been overlooked because their shorter
life expectancy and risk of death from other diseases
would make them less likely to be referred to Centers
of expertise. Having said as much, we can assume that
our figures might be only slightly underestimated be-
cause the registration system has been in use since
2002, because patient enrolment is linked with exemp-
tion from health care costs, and specialized diagnostic
facilities are only available at Centers of expertise - all
aspects that facilitate a more comprehensive patient
capture. The use of multiple sources to identify cases
(Centers of expertise, local public health authorities andpharmaceutical services) also helps to assure a good
coverage of the population.
Another limitation may relate to the contention that
clearly-defined diagnostic criteria are not available for all
the rare diseases monitored. We can assume, however,
that the diagnoses registered in our system are highly ac-
curate because they are established by clinicians at Cen-
ters of expertise for rare diseases, identified on the
strength of highly-standardized criteria, and routinely
audited by the Regional Health Authority. Although pa-
tient registration is linked to the issue of an exemption,
the quality of the clinical data collected is higher than in
an administrative database [15]. Furthermore, the level
of diagnostic detail adopted by the Veneto Regional
registry is also higher than in the list contained in the
Italian law in order to identify patients’ diagnoses as spe-
cifically as possible because the information system on
which the registry is based was designed to enable clini-
cians at the Centers of expertise to prescribe drugs and
devices on-line, draw up health care plans, and monitor
patients’ major clinical events. Linking the registration
process with the care dimension guarantees a good-
quality data collection and its maintenance over time.
An additional limitation of this study warrants specific
consideration. The list of rare diseases monitored by the
registry described here is not as exhaustive as the Orpha-
net one, for instance [55]. This limitation will be partially
overcome in future when the Italian Government is ex-
pected to add another 109 single diseases or groups of dis-
eases to its original list. For the time being, specific groups
of diseases, such as infectious diseases, respiratory disor-
ders, renal diseases, rheumatological diseases and rare tu-
mors, are particularly under-represented. Some diseases
(or groups of diseases), including cystic fibrosis and rare
tumors, are monitored in Italy and many other European
countries by dedicated registries that often have a long
history of data collection. Leaving rare cancers aside, the
list of rare diseases in the various groups monitored by
the registry described in the present work cover the 58%
of all those on the Orphanet list so, to obtain a global esti-
mate of the burden of rare diseases, we considered preva-
lence data from multiple sources and referring to groups
particularly under-represented in the Italian law (i.e. dis-
eases of the respiratory system, infectious diseases, renal
diseases and rheumatological diseases). The list of rare
diseases for which prevalence estimates are available and
updated regularly by Orphanet was therefore used to esti-
mate the overall prevalence of rare diseases not currently
monitored by our registry [50]. The prevalence of the vast
majority of the unmonitored entities is unknown or ex-
tremely low because these conditions are so rare that they
have been described in just a few individuals or families
worldwide (Figure 3), and this means that increasing the
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Figure 3 Percentage distribution of prevalence estimates of
rare diseases not currently monitored by the Veneto Region’s rare
diseases registry. Source: Orphanet Report Series - Prevalence of
rare diseases: Bibliographic data - June 2013 (Reference 50)
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being registered. After comparing our own list with the
Orphanet list, the overall estimated prevalence of all
the diseases not currently monitored by our registry is
3.3/1,000 population, which rises to a maximum of 19.5/
1,000, if we include rare tumors. However, a salami-slicing
effect can be seen for these conditions, that raises the
number of entities qualifying as rare diseases, starting
from common phenotypic conditions [56]. It can also be
argued that incidence is more appropriate than prevalence
as an indicator for estimating the burden of cancer at
population level [57]. This is because prevalent cancer
cases form a very heterogeneous group that – by defin-
ition –includes all individuals who have ever been diag-
nosed with cancer at any time in their life [58], so this
group can include people still receiving therapy as well as
disease-free survivors, whereas the prevalent cases of
other rare diseases are usually individuals living with long-
standing chronic conditions.
Strengths
Despite the above-mentioned limitations, we consider
the data presented here of some value because they stem
from a good-quality, fully-computerized population-
based registry. The monitoring system described here
not only provides epidemiological figures for a sizable
group of rare diseases that are useful for estimating the
magnitude of the problem at population level, it also en-
ables us to establish the relative contribution of different
nosological entities to the global burden of rare diseases.
Among others, four elements are fundamental to the
successful implementation of this type of registry: the
use of a shared web-based system; the feasibility of a
modular development of the infrastructure supportingthe registry; the "multi-data use" principle; and the regis-
try’s development within the framework of broader
health policies addressed to patients with rare diseases.
First, the use of a web-based system simplifies the data
collection process and offers economies of scale. The
use of a shared infrastructure can promote data collec-
tion on ultra-rare diseases, or conditions for which no
treatment is currently available, both situations in which
a dedicated registry would be difficult to establish and
maintain [59]. As demonstrated by the French experi-
ence too, involving health professionals from different
backgrounds sharing the same information system pro-
motes a multidisciplinary approach to patient care, which
is always a challenge, but especially when dealing with
complex rare conditions [60,61].
The second element (the modular approach used to
develop the information system) ensured a high level of
participation in the data collection process, enabling an
increasing number of health professionals working in
different care network settings to become involved, and
facilitating the adoption of the same information system
by other Italian regions.
The third element concerns the “multi-data use”
principle according to which the data output has to be
useful to people who input the data [62]. From the
patients’ standpoint, the system ensures a rapid infor-
mation flow, minimizing the time it takes to obtain
benefits, and simplifying the paperwork involved [63].
On the other hand, it enables users to produce on-line
statistics based on the data entered and to run searches
on all the contents, making the registry a powerful re-
search tool.
Finally, a key issue concerns the registry’s governance.
The legally mandatory involvement of governmental
bodies (the Regional Health Authorities in the decentra-
lized Italian National Health System scenario) in the
setup and maintenance of rare disease monitoring systems
guarantees the long-term sustainability of the registra-
tion process because it is the first step in the provision
of patient care. In addition, as the debate on orphan
drug post-marketing surveillance has underscored, the
availability of data from independent registries has become
very important for the purpose of orienting clinical prac-
tice and transparently supporting the decision-making
process [64]. In our view, public governance of such regis-
tries should be interpreted as evidence of the attention
that should be paid to rare disease patients by the commu-
nity as a whole.
Conclusions
This study outlines the complex epidemiological profile
of rare diseases at population level and emphasizes the
usefulness of a monitoring system for the purpose of
tackling rare diseases from a global perspective rather
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this field have also highlighted [20].
Alongside the debate regarding what value society
should attribute to rarity vis-à-vis more common med-
ical conditions, the figures and indicators presented here
should dispel any policy-maker’s doubts about allocating
resources to rare diseases because they might be per-
ceived as having only a marginal impact on the health of
the community.
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